Exome variants associated with asthma and allergy.

Area of Science:

• Genetics
• Immunology
• Bioinformatics

Background:

• The genetic underpinnings of asthma and allergy susceptibility, particularly concerning rare variants, remain largely uncharacterized.
• Previous studies have primarily focused on common variants, leaving a gap in understanding the role of rare genetic variations in allergic diseases.

Purpose of the Study:

• To identify and characterize rare genetic variants associated with asthma, allergic rhinitis, and atopic dermatitis using a large-scale exome sequencing dataset.
• To compare newly identified variants and genes with those previously discovered through genome-wide association studies (GWAS) and other sequencing approaches.
• To pinpoint novel pharmacological targets within identified genes for potential therapeutic interventions in allergic diseases.

Main Methods:

• Secondary analysis of exome sequencing data from 281,104 UK Biobank participants.
• Identification and tabulation of variants of interest (VOI) significantly associated with asthma, allergic rhinitis, and atopic dermatitis.
• Annotation of shared genes and comparison with existing genetic association study findings.

Main Results:

• 354 variants of interest (VOI) were significantly associated with the studied allergic conditions.
• These VOI predominantly cluster in chromosomal regions 6 and 17, with 321 unique VOI identified in 122 unique genes after filtering.
• A substantial proportion (85%) of previously identified genes via common GWAS SNPs were not replicated, highlighting the distinct contribution of rare variants. Key implicated pathways include interferon-gamma and IL-33 signaling.

Conclusions:

• This study identifies numerous rare variants and genes linked to asthma and allergic diseases, many of which are novel.
• Genes involved in interferon-gamma and IL-33 signaling pathways are crucial in allergic disease pathogenesis.
• Identified genes, including ST2/IL1RL1, TLR1, and IL13, represent promising new targets for developing personalized pharmacotherapies for allergic conditions.